Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.07 USD | +6.79% | +7.13% | +21.18% |
Apr. 17 | IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets | MT |
Apr. 17 | IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration | CI |
Business Summary
Number of employees: 224
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Engineered Immunoglobulin M Antibodies
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +99.25% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +99.25% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 03-01-31 |
Misbah Tahir
DFI | Director of Finance/CFO | 49 | 18-12-31 |
T. S. Harigopal
COO | Chief Operating Officer | - | 20-12-31 |
Chris Takimoto
CTO | Chief Tech/Sci/R&D Officer | 65 | 21-07-28 |
Bruce Keyt
CTO | Chief Tech/Sci/R&D Officer | 71 | 09-12-31 |
Lisa Wax
LAW | General Counsel | - | 20-12-31 |
Corporate Officer/Principal | - | 17-12-31 | |
George Gauthier
PRN | Corporate Officer/Principal | 52 | 21-04-11 |
Steven Weber
AUD | Comptroller/Controller/Auditor | 48 | 22-02-28 |
Paul Graffagnino
LAW | General Counsel | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 21-01-25 |
M. Wilsey
BRD | Director/Board Member | 71 | 19-01-30 |
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 03-01-31 |
Michael Lee
BRD | Director/Board Member | 45 | 19-06-30 |
Julie Hambleton
BRD | Director/Board Member | 66 | 18-08-14 |
Director/Board Member | 55 | 18-07-31 | |
Director/Board Member | 43 | 18-07-31 | |
William Strohl
BRD | Director/Board Member | 71 | 18-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 25,500,383 | 0 | 0 | 37.00 % |
Stock B | 1 | 33,286,205 | 21,753,449 ( 65.35 %) | 0 |
Company contact information
IGM Biosciences, Inc.
325 East Middlefield Road
94043, Mountain View
+650 965 7873
http://www.igmbio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.18% | 594M | |
+8.96% | 105B | |
-1.43% | 104B | |
+5.33% | 22.94B | |
-12.15% | 22.34B | |
-6.45% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- IGMS Stock
- Company IGM Biosciences, Inc.